SEC Form 4 · accession 0001615774-17-007355
ANAVEX LIFE SCIENCES CORP. · AVXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher U Missling
Officer — President and CEO · Director
Period of report
Dec 13, 2017
Accepted (ET)
Dec 15, 2017 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314052
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.30 | Dec 13, 2017 | A | 400,000 | A | — | Dec 13, 2027 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1The options shall vest quarterly over a three-year period commencing on March 31, 2018.